Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

Many say they felt attacked by debilitating waves of sound and pressure known as "Havana syndrome." Sunday, 60 Minutes reported… U.S. defense official had ‘Havana syndrome’ symptoms during a ...